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Chlamydia pneumoniae antigens facilitate
experimental aortic dilatation: Prevention with
azithromycin
Jeymi Tambiah, FRCS, and Janet T. Powell, MD, London, United Kingdom
Objective: The purpose of this study was to investigate whether Chlamydia pneumoniae (live, antigens, or polysaccharide)
cause abdominal aortic aneurysm in a susceptible animal host with appropriate drug reversal.
Methods: At laparotomy, preparations of C pneumoniae (live, formalin-inactivated, and heat-inactivated) in calcium
chloride were applied to the adventitial surface of the abdominal aorta of rabbits fed a cholesterol-enriched diet. Aortic
diameter was measured with ultrasonography. After 3 weeks, immunohistochemistry was used to detect aortic C
pneumoniae and macrophages. Presence of C pneumoniae DNA also was assessed.
Results: At high doses (5  107organisms) periaortic application of both live and formalin-inactivated preparations
resulted in doubling of aortic diameter after 3 weeks, from 2.0 0.5 mm to 4.3 1.3 mm (P < .02). C pneumoniae DNA
and antigens, together with a heavy macrophage infiltrate, were detected in the dilated aorta. In contrast, periaortic
application of heat-inactivated preparations resulted in minimal macrophage influx and aortic dilatation. Treatment of
rabbits with azithromycin or carprofen for 10 days after laparotomy abolished the effects of formalin-inactivated C
pneumoniae on aortic dilatation. Azithromycin reduced the number of macrophages in the aortic wall more effectively
than carprofen.
Conclusion: Because membrane antigenicity is retained in formalin-inactivated but not heat-inactivated organisms, in this
experimental model, chlamydial membrane antigens (rather than live organisms) appear to cause the aneurysmal
dilatation and associated macrophage recruitment. Azithromycin is likely to reverse these effects with an antiinflamma-
tory mechanism. (J Vasc Surg 2002;36:1011-7.)
At the beginning of the 20th century, Sir William Osler
proposed that infectious agents could be important in the
pathogenesis of atherosclerosis. At the beginning of the
21st century, the association between atherosclerosis and
infection with Chlamydia pneumoniae is accepted widely.
Most of this evidence has been seroepidemiologic1-4 or
pathologic.4-6 Cell biology has revealed some of the poten-
tial molecular mechanisms whereby infection with C pneu-
moniae might cause or accelerate atherosclerotic disease.
Such mechanisms include the ability of the chlamydial heat
shock protein to stimulate cytokine and metalloproteinase
secretion from macrophages and the increased procoagu-
lant functions of endothelium and smooth muscle cells
after infection with C pneumoniae.7,8
Abdominal aortic aneurysm (AAA) is a common con-
dition in men more than 65 years of age. Traditionally,
AAA was viewed as a complication of atherosclerosis.9
Today, the crucial pathologic processes underlying the
degeneration of the aortic media in aneurysms appear to be
inflammation and proteolysis.10 There is also a link with C
pneumoniae infection. In a small study, Juvonen and col-
leagues11 showed that more than half of patients with AAA
had a high serum antibody immunoglobulin G (IgG) titre,
an even larger proportion showed evidence of chlamydial
elementary bodies or antigens in aortic wall biopsies, and all
biopsies assessed for the presence of chlamydial DNA tested
positive. This has been followed by further studies, princi-
pally with use of the polymerase chain reaction to detect
DNA, which showed evidence of chlamydial infection in
50% to 100% of aortic biopsies.12-14 No evidence indicates
whether the association between the presence of C pneu-
moniae and AAA is casual or causal.
Traditionally, where an infectious agent causes a spe-
cific disease, all three of Koch’s postulates must be satisfied.
The first two of these postulates have been satisfied for the
association between C pneumoniae and atherosclerosis: the
organism is found in association with the disease, and the
microorganism can be isolated and grown in pure cul-
ture.15 The third postulate, that disease can be reproduced
in a susceptible host (animal) with inoculation with the
organism, has been more difficult to prove. Some evidence
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exists that high doses of C pneumoniae, administered intra-
nasally, accelerate intimal thickening and the development
of atherosclerosis in cholesterol-fed rabbits.16 Treatment of
the rabbits with azithromycin prevented the accelerated
intimal thickening.16
In man, the causative role of C pneumoniae has been
and continues to be addressed through antibiotic trials for
the secondary prevention of coronary events. These trials
have had mixed results, and currently, antibiotic therapy to
reduce vascular risk appears inappropriate.17,18 A pilot trial
in 34 patients has indicated that doxycycline may reduce
the growth rate of small AAAs, although no effect was seen
on chlamdial antibody titres.19
In this study, we have tried to satisfy Koch’s third
postulate for AAA. Like previous workers, we have used
rabbits fed a cholesterol-enriched diet. In these animals, the
periaortic application of calcium chloride and thioglycollate
(a nonspecific macrophage activator) resulted in a two-fold
increase in aortic diameter within 3 weeks, although at this
time point, rupture was only observed in approximately 2%
of cases.20 The calcium chloride causes endothelial dys-
function, increased aortic permeability, and calcification of
the media; thioglycollate is a nonspecific macrophage stim-
ulant, and in rabbits, hypercholesterolemia increases mac-
rophage activity.20 We have replaced the thioglycollate
with either live C pneumoniae, formalin-inactivated prepa-
rations (with preservation of antigenicity7), or heat-inacti-
vated preparations (with preservation of lipopolysaccharide
but not antigenicity7) and investigated the effects on aortic
diameter and macrophage influx.
METHODS
New Zealand white rabbits (2.2 to 2.8 kg) were subject
to laparotomy in accordance with approved protocols for
the care and use of laboratory animals (PIL70/4221). The
rabbits were fed either a standard chow or a cholesterol-
enriched diet (Stanrab  0.5% cholesterol; Lillico, Betch-
worth, United Kingdom) starting 2 days before surgery: all
rabbits initially were seronegative for chlamydial antigens.
Anesthesia was obtained with a combination of intramus-
cular fentanyl citrate (Hypnorm, Roche, United Kingdom)
and intravenous midazolam (Hypnovel, Janssen, United
Kingdom), with oxygen at 2 L/min delivered with facial
mask. After fentanyl citrate injection, before laparotomy,
the diameter of the abdominal aorta (mean of three anteri-
or-posterior readings) was measured with ultrasonography
(Aloka SSD-500 with 7.5-MHz probe; Keymed, Sou-
thend, United Kingdom), limits of agreement 0.2 mm.20
The abdomen was opened through a midline incision, and
the infrarenal aorta was dissected, with care not to damage
any lumbar vessels. Calcium chloride solutions (0.2
mol/L) were applied at a slightly lower concentration than
described previously20 to avoid excessive aortic calcifica-
tion. C pneumoniae were applied, to the infrarenal aorta, in
the calcium chloride solution (total volume, 4.0 mL, con-
taining 5  101 to 5  107 organisms, of which 10% to
15%, by weight, were retained on the applicators). The
chlamydial preparations (live, formalin-inactivated, and
heat-inactivated) were a kind gift from Dr Brenda Thomas
(Imperial College at St Mary’s, London); heat and forma-
lin-inactivated preparations had no replicative activity in
culture. Similarly, sodium thioglycollate (0.1 mol/L) was
applied in 3.5 to 4.0 mL of calcium choride solution. The
abdomen was sutured with mass closure with 3/0 prolene,
followed by subcuticular skin suture (3/0 Dexon, Norr-
talje, Sweden). Some rabbits were treated with oral
azithromycin (4 mg before surgery, followed by 4 mg/d
for 10 days after surgery) or subcutaneous carprofen (10
mg before surgery and on the first postoperative day fol-
lowed by 5 mg/d for 10 days). Three weeks later, the
diameter of the aorta was again measured with ultrasonog-
raphy, after fentanyl citrate injection, a serum sample re-
moved for the measurement of cholesterol (with a colori-
metric enzyme assay kit, Boehringer, Lewes, United
Kingdom), and the animals killed. Some animals had the
aorta and other vessels fixed with perfusion with 5% glutar-
aldehyde at a pressure of 100 cm water. Where the aorta
was not perfusion fixed, a sample was frozen at70° C for
later extraction of DNA and the remainder fixed in forma-
lin.
All aortas were taken in cross section and processed
with hematoxylin and eosin and elastic van Gieson staining.
The stained sections were assessed by a single consultant
histopathologist. Macrophages were further identified with
the antibody RAM-11 (Dako, Ely, United Kingdom) at 1
in 50 dilution and elemental bodies of C pneumoniae with
the fluoroscein isothiocyanate conjugated monoclonal an-
tibody TT-401 (Washington Research Foundation, Seat-
tle, Wash) at 1 in 50 dilution. Stained macrophages were
counted by a single observer, blind to the treatments ap-
plied to each specimen. For quantitative analysis, cells from
consecutive, circumferential, nonoverlapping aortic fields
were examined under a digital image capturing light micro-
scope and cell counting performed with AnalySiS (Percep-
tive Instruments, Steeple Bumpstead, United Kingdom)
image analysis software. Aortic wall thickness (lumen to
external elastic lamina) was measured in four quadrants,
and the mean was calculated.
DNA was extracted from frozen pulverized tissue with
a commercial kit (Dneasy, Qiagen, Crawley, United King-
dom). Amplification of the omp-1 and -actin genes was
performed with 50 to 100 ng of template DNA, in a 50-L
reaction mixture containing 1.5 to 2.5 mmol/L MgCl2, 2
U Taq (Promega, Southampton, United Kingdom) poly-
merase, 10 pmol primers (Perkin-Elmer, Warrington,
United Kingdom), 1 volume buffer “B” (Promega,
Southampton, United Kingdom). and 200 mol/L de-
oxynucleotide triphosphates (Pierce & Warriner, Chester,
United Kingdom. The -actin primers (5’-3’) were AT-
CATGTTTGAGACCTTCAACACCCC and CTT-
GATCTTCATTGTGCTGGGTGCCA. If the -actin
gene could not be amplified from the DNA sample, it was
subject to further phenol-chloroform extraction and etha-
nol precipitation. The first and second round primers (5’-
3’) for amplification of the omp-1 gene were GTTGT-
TCATGAAGGCCTACT, TGCATAACCTACGGTTT
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and TTTAGATCATGGTGTCATTCGC, AAGGT-
TCATCCTTGAAGGCA, respectively. This nested reac-
tion can be sensitive to polymerase chain reaction (PCR)
inhibition,5 so that if no amplification was achieved, the
DNA was diluted 10-fold and spiked and tested in the
presence and absence of cloned TWAR DNA. Cloned
TWAR183 DNA was the kind gift of Dr Nessa Carey,
Imperial College at Charing Cross, United Kingdom, and
the sensitivity of the nested omp-1 gene amplification was
70 gene copies.
Most data were analysed with analysis of variance
(ANOVA), giving Fischer exact significance for paired
comparisons. Aortic diameters were compared with paired t
tests. Numerical values are reported as mean  standard
deviation, unless otherwise stated.
RESULTS
Effect of C pneumoniae on aortic diameter. In
rabbits fed a cholesterol-enriched diet, periaortic applica-
tion of 0.2 mol/L CaCl2 did not result in an increase in
aortic diameter after 3 weeks (negative control; Table).
After 3 weeks, the average weight gain of rabbits was 62 g
and the median serum cholesterol concentration was 72
mmol/L. Periaortic application of 0.2 mol/L CaCl2 with
0.1 mol/L thioglycollate resulted in a two-fold increase in
aortic diameter after 3 weeks (positive control; Table).
Periaortic application of 0.2 mol/L CaCl2 containing 5 
107 organisms of live C pneumoniae resulted in a two-fold
increase in aortic diameter after 3 weeks (Table). With the
same dose of organism, we then compared the effect of live,
formalin-inactivated, and heat-inactivated C pneumoniae
on aortic dilatation and macrophage influx. Periaortic ap-
plication of formalin-inactivated C pneumoniae (5  107
organisms) in 0.2 mol/L CaCl2 also resulted in a two-fold
increase in aortic diameter at 3 weeks, but application of
heat-inativated C pneumoniae had no significant effect on
aortic diameter (Table). Lower doses of formalin-inacti-
vated C pneumoniae (5  101to 5  105 organisms) did
not have a significant effect on aortic diameter at 3 weeks
(data not shown).
Persistence of C pneumoniae in postmortem aorta.
The presence of the omp-1 gene (with PCR) and elemental
bodies (TT-401 immunofluorescence) 3 weeks after peri-
aortic application of chlamydia preparations were assessed.
For aortas treated with live C pneumoniae (5 107 organ-
isms), the omp-1 gene was amplified successfully from two;
in two further aortas, there was evidence of PCR inhibition,
and all samples showed positive staining for elemental
bodies with the monoclonal antibody TT-401. For five
rabbits treated with the full dose of formalin-inactivated C
pneumoniae, the omp-1 gene was successfully amplified
from two aortas; the remaining three showed evidence of
PCR inhibition, but all five showed positive staining with
TT-401 (Fig 1). In contrast, for five rabbits treated with
heat-inactivated C pneumoniae, there was no evidence of
either the omp-1 gene or PCR inhibition and none of the
aortas stained positively with TT-401 (a summary of the
TT-401 staining results is given in the Table). However,
the omp-1 gene could be amplified from splenic DNA from
these latter animals. The omp-1 gene also could be ampli-
fied from undilated aortas, where formalin-inactivated C
pneumoniae (5 107 organisms) had been applied in NaCl
rather than CaCl2 or where rabbits had not received a high
cholesterol diet. Therefore, there was DNA and immuno-
histochemical evidence for aortic retention of both live and
formalin-inactivated organisms but not for the heat-inacti-
vated organisms.
Inflammatory infiltrates and macrophage recruit-
ment. After 3 weeks of cholesterol feeding, there were
only scant numbers of macrophages (6  6 per unit area)
and few other inflammatory cells in the abdominal aorta.
When aneurysmal dilatation was elicited with periaortic
application of CaCl2 and thioglycollate, macrophages were
the dominant inflammatory cell recruited into the aorta,
with a scattering of lymphocytes and occasional giant cells
in calcified areas.20 There was no significant increase in the
number of macrophages (27  15 per unit area) or lym-
phocytes after aortas had been treated with heat-inactivated
C pneumoniae in CaCl2. After aorta had been treated with
live or formalin-inactivated C pneumoniae (5 107 organ-
isms), the number of macrophages increased significantly
to 324 144 and 143 69 and per unit area, respectively
(ANOVA, P  .01), and there was a modest increase in
lymphocytes. At a lower dose (5  105) of formalin-
inactivated organism, macrophages (53 19 per unit area)
were confined largely to the media, but at even lower doses
Effect of different C pneumoniae preparations on aortic diameter, 3 weeks after periaortic application
n
Mean aortic
diameter with
ultrasonography:
initial (mm)
Mean aortic
diameter with
ultrasonography:
final (mm)
TT-401
staining
at 3 weeks
Added to 0.2 mol/L CaCl2 4 2.8  0.4 3.0  0.5 0/4
0.1 mol/L thioglycollate 6 2.8  0.4 4.8  0.4* nd
C pneumoniae live 4 2.0  0.5 4.3  1.3* 4/4
C pneumoniae heat-inactivated 5 2.4  0.2 3.5  0.5 0/5
C pneumoniae formalin-inactivated 7 2.4  0.7 4.3  0.6* 5/5
Chlamydial doses were 5  107 organisms.
Results are given as mean  standard deviation.
*Significant increase in diameter compared with initial diameter (paired t test, P  .02).
nd, Not determined.
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of organism (5  103 or 5  101), negligible macrophage
staining (28  18 and 19  15 per unit area, respectively)
or lymphocytes were observed.
Intervention with azithromycin or carprofen. Rab-
bits (n  12) were randomly allocated to receive a 10-day
postoperative course of azithromycin, carprofen (a nonste-
roidal antiinflammatory drug suitable for use in rabbits), or
no treatment: formalin-inactivated C pneumoniae (5 107
organisms) in CaCl2 was applied to the abdominal aorta.
The increase in aortic diameter, measured after 3 weeks, is
shown in Fig 2: only the animals with no drug treatment
showed an increased aortic diameter (ANOVA, P  .01).
Representative immunostaining for macrophages, with
RAM-11, is shown in Fig 3. In the no treatment group,
there was evidence of medial calcification, disruption of
normal tissue architecture, and a transmural infiltrate of
inflammatory cells, predominantly macrophages. After
treatment with azithromycin, aortic calcification was still
evident, but only a few macrophages surrounding the cal-
cified areas were observed. Similarly, the number of ele-
mental bodies detected with staining with TT-401 was
markedly diminished (Fig 1 , panel C). After treatment with
carprofen, medial aortic calcification with a considerable
number of macrophages and scattered lymphocytes was still
evident, but the inflammatory cells were confined princi-
pally to the media. The macrophage counts/unit area in the
no treatment, carprofen, and azithromycin groups were
158 44, 109 5, and 3 4, respectively (ANOVA, P
.01).
Fig 1. C pneumoniae elementary bodies visualized with antibody
TT-401. Sections of formalin-fixed tissue have been stained with
fluorescein-conjugated TT-401 (1 in 100 dilution), and scale bar
represents 10 m. Panel A shows control aorta, 3 weeks after
periaortic application of 0.2 mol/L CaCl2 only. There is only
background fluorescence. Panel B shows aorta of rabbit, 3 weeks
after periaortic application of formalin-inactivated C pneumoniae
(5 107 organisms) in 0.2 mol/L CaCl2. High density of elemen-
tal bodies is evident. Panel C shows aorta from rabbit treated as in
panel B but given a 10-day course of azithromycin. Density of
elemental bodies is reduced compared with panel B.
Fig 2. Effect of azithromycin and carprofen on aortic dilatation
provoked by periaortic application of formalin-inactivated C pneu-
monia. Results show mean (standard deviation) of percentage
increase in aortic diameter, with four animals in each group.
Treatment with either azithromycin or carprofen abolished in-
crease in aortic diameter (ANOVA, P  .02).
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DISCUSSION
Our initial results showing that the periaortic applica-
tion of live C pneumoniae provoked aortic dilatation sug-
gested possible proof of Koch’s third postulate for AAA;
further experiments disproved this possibility. Live organ-
isms were not essential to provoke aortic dilatation, and
similar results were obtained with inactivated organisms
with antigen preservation (formalin-inactivated organ-
isms). For both live and formalin-inactivated organisms,
there was persistence of chlamydial antigens in the aortas
harvested at 3 weeks. In contrast, preservation of lipopoly-
saccharide with denaturation of antigens (heat-inactivated
organisms) did not provoke an increase in aortic diameter,
providing confirmation of previous work showing that
bacterial lipopolysaccharide did not provoke aortic dilata-
tion (Walton LJ, unpublished observations). Moreover,
with heat-inactivated preparations, no organisms could be
detected in the aorta after 3 weeks. Therefore, it appears
that chlamydial antigen persistence, rather than infection,
was associated with the aortic dilatation in this model.
For safety reasons, we pursued most of our further
investigations with formalin-inactivated preparations of C
pneumoniae. Treatment with either azithromycin or a non-
steroidal antiinflammatory drug (carprofen) proved effec-
tive in preventing the aortic dilatation stimulated by forma-
lin-inactivated organisms.
Azithromycin is the drug previously used to retard the
development of atherosclerosis in rabbits and in human
prevention trials.16-18,21 Azithromycin is recognized to
have antiinflammatory and antimacrophage activity, and
this alternative mode of drug action must be consid-
ered.17,22 Recent evidence also shows that azithromycin
improves endothelial function in patients with evidence of
previous C pneumoniae infection.23 Therefore, azithromy-
cin might improve the endothelial dysfunction resulting
from periaortic application of calcium chloride.20
In this experimental model, aortic dilatation always is
accompanied by a heavy transmural influx of macro-
phages.20 Chlamydial antigens and thioglycollate (a non-
specific macrophage activator) appeared to provoke a sim-
ilar magnitude of macrophage influx. Carprofen prevented
aortic dilatation but had only a marginal effect on the
number of macrophages in aorta. Carprofen will inhibit
cyclooxygenase 2 and through this mechanism is likely to
Fig 3. Aortic macrophages visualized with antibody RAM-11. Formalin-fixed sections have been stained with
RAM-11 (brown) and counterstained with hematoxylin; scale bar represents 50m. Panel A shows normal rabbit aorta,
3 weeks after periaortic application of NaCl. Panel B shows rabbit aorta 3 weeks after periaortic application of
formalin-inactivated C pneumoniae (5  107 organisms) in 0.2 mol/L CaCl2. Tissue architecture is disrupted, with
evidence of medial calcification and intense transmural infiltrate of macrophages. Panel C shows aorta from rabbit
treated as in panel B but given 10-day course of carprofen. There is still evidence of medial calcification, but fewer
macrophages mainly confined to media near areas of calcification. Panel D shows aorta from rabbit treated as in panel
B but given 10-day course of azithromycin. There is still evidence of medial calcification but only scant presence of
macrophages.
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inhibit the formation of inflammatory prostanoid media-
tors. In man, and animal models, there is evidence to show
that inhibition of cyclooxygenase 2 slows aneurysm growth
and reduces the production of inflammatory cytokines in
the aorta.24,25 Both macrophage recruitment and macro-
phage activation are likely to be necessary to cause aortic
dilatation in our experimental model. In addition, our
study confirms that azithromycin, at least in rabbits, has
specific antimacrophage effects. A similar mechanism may
underlie the early beneficial clinical effects of azithromycin
that have been reported.21
There has been considerable discussion as to whether
there is an infectious basis for atherosclerosis. Recent evi-
dence from studies with apolipoprotein E knockout mice
shed doubt on this possibility.26,27 However, there has also
been considerable discussion of the other potential mech-
anisms of how C pneumoniae could aggravate atheroscle-
rosis through antigen mimicry and immune mechanisms,
and the persistence of chlamydial antigens in AAA tissue has
been recognized.28-30 Our findings are in keeping with
such mechanisms.
Inflammation and proteolysis are the twin processes
considered to underlie aortic dilatation, with matrix metal-
loprotease-9 being considered as one of the pivotal proteo-
lytic enzymes involved in aneurysm expansion in man and
experimental animals.10,31,32 The chlamydial membrane
antigens omp-2 and major outer membrane protein and
the secreted heat shock protein-60 stimulate the secretion
of matrix metalloprotease-9 from human macrophages in
vitro.33 A role for chlamydial antigens in compounding
other risk factors for aneurysmal disease is in keeping with
the findings of Meijer et al,14 who reported that membrane
antigens, specific to C pneumoniae, were found in all sam-
ples of AAA, even in the absence of DNA and heat shock
protein. In our experimental model, such membrane anti-
gens could be responsible for the inflammatory response,
with macrophage recruitment and activation.
Strengths of our study include the formal testing of
Koch’s third postulate and the use of active and inactivated
organisms, but there are several limitations. First, although
the experimental model has histologic similarities with the
human disease, the conditions required to cause rapid
aneurysmal dilatation are extreme: an inflammatory stimu-
lus in the presence of high serum cholesterol concentra-
tions and sufficient calcium chloride to cause endothelial
dysfunction, transmural injury, and calcification.20 Similar
extreme conditions also cause carotid artery aneurysms in
rabbits.34 Second, large inoculates of formalin-inactivated
C pneumoniae were required to cause aortic dilatation,
although similar size inoculates were necessary to potenti-
ate atherosclerosis in cholesterol-fed rabbits.16 Third,
much larger groups of animals would have been necessary
to show a dose-dependent effect on aortic diameter in-
crease. Fourth, the small number of animals in each exper-
imental group (in accord with current ethical guidelines)
permits only the detection of large effects.
In summary, the evidence from this experimental
model indicates that infection with C pneumoniae could
accentuate antigen-dependent inflammatory pathways in
the aortic wall to contribute to experimental AAA develop-
ment. However, such extrapolation from rabbit to man
must be made with extreme caution. Although antigen-
dependent inflammatory pathways are likely to contribute
to aneurysm development, there is still no evidence that
infection with C pneumoniae causes AAA.
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